Clinical Trial

TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated September 26, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
1. Phase Ib study stage: Primary objective: To evaluate the efficacy and safety Secondary objectives: To evaluate the population pharmacokinetic characteristics 2. Phase II study stage: Primary objective: To evaluate the efficacy Secondary objectives: To evaluate the safety
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-05; most recent amendment 2025-09-22.
Status change: Recruiting → Active, Not Recruiting 2025-09-22
Status change: Not Yet Recruiting → Recruiting 2024-08-11
Trial Details
NCT Number NCT06169722
Lead Sponsor Beijing Tide Pharmaceutical Co., Ltd
Conditions GVHD, Chronic
Enrollment 60 participants
Start Date 2024-02-06
Primary Completion 2026-02 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2025-09-26